Can Valproic Acid be an Inducer of Clozapine Metabolism?

Abstract

Introduction: Prior clozapine studies indicated no effects, mild inhibition or induction of valproic acid (VPA) on clozapine metabolism. The hypotheses that (i) VPA is a net inducer of clozapine metabolism, and (ii) smoking modifies this inductive effect were tested in a therapeutic drug monitoring study.

Methods: After excluding strong inhibitors and inducers, 353 steady-state total clozapine (clozapine plus norclozapine) concentrations provided by 151 patients were analyzed using a random intercept linear model.

Results: VPA appeared to be an inducer of clozapine metabolism since total plasma clozapine concentrations in subjects taking VPA were significantly lower (27% lower; 95% confidence interval, 14–39%) after controlling for confounding variables including smoking (35% lower, 28–56%).

Discussion: Prospective studies are needed to definitively establish that VPA may (i) be an inducer of clozapine metabolism when induction prevails over competitive inhibition, and (ii) be an inducer even in smokers who are under the influence of smoking inductive effects on clozapine metabolism.

Key words

clozapine - pharmacokinetics - metabolism - enzyme induction - drug interactions - therapeutic drug monitoring - valproic acid - smoking - tobacco - random-effects linear model

• References

• 1 Fischer V, Vogels B, Maurer G et al. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 1992; 260: 1355-1360
• 2 Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100: 4-22
• 3 Fang J, Coutts RT, McKenna KF et al. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 592-599
• 4 de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol 2003; 6: 57-72
• 5 Jaquenoud Sirot E, Knezevic B, Morena GP et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009; 29: 319-326
• 6 Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30: 1206-1227
• 7 Wetzel H, Anghelescu I, Szegedi A et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998; 18: 2-9
• 8 de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005; 46: 262-273
• 9 Facciola GA, Avenoso E, Spina E et al. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit 1998; 20: 628-630
• 10 de Leon J, Santoro V, D’Arrigo C et al. Interactions between antiepileptics and second-generation antipsychotics. Exp Opin Drug Met Toxicol 2012; 8: 2-24
• 11 Chen Y, Goldstein JA. The transcriptional regulation of the human CYP2C genes. Curr Drug Metab 2009; 10: 567-578
• 12 de Leon J, Chambers A, Hyatt M et al. A practitioner’s guide for prescribing carbamazepine for adults with intellectual disabilities. In de Leon J, de Leon J, Chambers A, Hyatt M, Shertz E, Aug R, Sinclair K. et al. ed. A Practitioner’s guide for prescribing anticonvulsants and mood stabilizers for adults with intellectual disabilities. New York, NY: Springer Verlag; 2012: 19-54
• 13 de Leon J, Spina E, Diaz FJ. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing and translation into a message understandable to practicing clinicians (editorial). J Clin Psychopharmacol 2009; 29: 201-205
• 14 Hiemke C, Baumann P, Bergemann N et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44: 195-235
• 15 de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1059-1063
• 16 Diaz FJ, Santoro V, Spina E et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008; 41: 81-91
• 17 Doude van Troostwijk LJ, Koopmans RP, Vermeulen HD et al. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. Eur J Pharm Sci 2003; 20: 451-457
• 18 Raedler TJ, Hinkelmann K, Wiedemann K. Variability of the in vivo metabolism of clozapine. Clin Neuropharmacol 2008; 31: 347-352
• 19 Dailly E, Urien S, Chanut E et al. Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 699-703
• 20 Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823-832
• 21 Ozdemir V, Kalow W, Posner P et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol 2002; 21: 398-407
• 22 de Leon J, Chambers A, Hyatt M et al. A practitioner’s guide for prescribing valproate for adults with intellectual disabilities. In de Leon J, de Leon J, Chambers A, Hyatt M, Shertz E, Aug R, Sinclair K. et al. ed. A Practitioner’s guide for prescribing anticonvulsants and mood stabilizers for adults with intellectual disabilities. New York, NY: Springer Verlag; 2012: 419-460
• 23 Centorrino F, Baldessarini RJ, Kando J et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994; 151: 123-125
• 24 Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994; 36: 487-488
• 25 Longo LP, Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine. Am J Psychiatry 1995; 152: 650
• 26 Conca A, Beraus W, Konig P et al. A case of pharmacokinetic interference in comedication of clozapine and valproic acid. Pharmacopsychiatry 2000; 33: 234-235
• 27 Ulrich S, Baumann B, Wolf R et al. Therapeutic drug monitoring of clozapine and relapse – a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003; 41: 3-13
• 28 Wong JO, Leung SP, Mak T et al. Plasma clozapine levels and clinical response in treatment - refractory Chinese schizophrenic patients. Prog Neuro-Psychopharmacol Biol Psychiatry 2006; 30: 251-264
• 29 Riesselman A, Strobl B, Cooley AT et al. A case report that suggested that aspirin effects on valproic acid metabolism may contribute to valproic acid’s inducer effects on clozapine metabolism. J Clin Psychopharmacol 2013; 33: 812-814
• 30 Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32: 554-563
• 31 DeVane CL. Pharmacokinetics, drug interactions and tolerability of valproate. Psychopharmacol Bull 2003; 37 (Suppl. 02) 25-42
• 32 Janssen Pharmaceuticals, Inc Invega^TM Extended-release tablets highlights. Available at http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916 – accessed January 11, 2014
• 33 McLaughlin DB, Andrews JA, Hooper WD et al. Apparent autoinduction of valproate beta-oxidation in humans. Br J Clin Pharmacol 2000; 49: 409-415
• 34 Cerveny L, Svecova L, Anzenbacherova E et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 2007; 35: 1032-1041
• 35 Citrome L, Josiassen R, Bark N et al. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005; 45: 89-93
• 36 Bergemann N, Kress KR, Abu-Tair F et al. Valproate lowers plasma concentration of olanzapine. J Clin Psychopharmacol 2006; 26: 432-434
• 37 Haslemo T, Olsen K, Lunde H et al. Valproic acid significantly lowers serum concentrations of olanzapine – an interaction effect comparable with smoking. Ther Drug Monit 2012; 34: 512-517
• 38 Spina E, D’Arrigo C, Santoro V et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug Monit 2009; 31: 758-763
• 39 Vucićević K, Miljković B, Pokrajac M et al. The influence of drug-drug interaction and patients’ characteristics on valproic acid’s clearance in adults with epilepsy using nonlinear mixed effects modeling. Eur J Pharm Sci 2009; 38: 512-518
• 40 de Leon J. False negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part I: Focus on epilepsy. J Clin Psychopharmacol 2014; 34: 177-183
• 41 de Leon J. False negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part II: Focus on bipolar disorder. J Clin Psychopharmacol 2014; 34: 177-183
• 42 de Leon J, Diaz FJ, Spina E. Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied. J Clin Psychiatry 2010; 71: 957-958
• 43 Choong E, Rudaz S, Kottelat A et al. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. J Pharm Biomed Anal 2009; 50: 1000-1008
• 44 American Pharmacist Association . Drug information handbook. 21^st ed. Hudson, OH: Lexi-Comp Inc; 2012
• 45 Diaz FJ, Rivera TE, Josiassen RC et al. Individualizing drug dosage by using a random intercept linear model. Stat Med 2007; 26: 2052-2073
• 46 Diaz FJ, Cogollo MR, Spina E et al. Drug dosage individualization based on a random-effects linear model. J Biopharm Stat 2012; 22: 463-484
• 47 Diaz FJ, Yeh HG, de Leon J. Role of statistical random-effects linear models in personalized medicine. Curr Pharmacogenomics Person Med 2012; 10: 22-32
• 48 Gough K, Hutchison M, Keene O et al. Assessment of dose proportionality: Report from the statisticians in the Pharmaceutical industry/Pharmacokinetics UK Joint Working Party. Drug Information J 1995; 29: 1039-1048
• 49 Dobrinas M, Cornuz J, Oneda B et al. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011; 90: 117-125
• 50 Gabbay V, O’Dowd MA, Mamamtavrishvili M et al. Clozapine and oral contraceptives: a possible drug interaction. J Clin Psychopharmacol 2002; 22: 621-622
• 51 Gibbons RD, Hedeker D, DuToit S. Advances in analysis of longitudinal data. Annu Rev Clin Psychol 2010; 6: 79-107
• 52 Chang WH, Lin SK, Lane HY et al. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 723-739
• 53 Sachse C, Ruschen S, Dettling M et al. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. Clin Pharmacol Ther 1999; 66: 431-438
• 54 Rahimi R, Abdollahi M. An update on the ability of St. John’s wort to affect the metabolism of other drugs. Expert Opin Drug Metab Toxicol 2012; 8: 691-708
• 55 Botts S, Diaz FJ, Santoro V et al. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1453-1458